Search

Author/Creator Llorin-Sangalang, Judith

1. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Issue 8 (August 2022)

Authors:
Pagel, John M; Soumerai, Jacob D; Reddy, Nishitha; Jagadeesh, Deepa; Stathis, Anastasios; Asch, Adam; Salman, Huda; Kenkre, Vaishalee P; Iasonos, Alexia; Llorin-Sangalang, Judith; Li, Joanne; Zelenetz, Andrew D
Journal:
Lancet oncology
Issue:
Volume 23:Issue 8(2022)
Page Start:
1021
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search